NASDAQ:PRME Prime Medicine (PRME) Stock Price, News & Analysis $3.90 -0.40 (-9.19%) As of 03:49 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Prime Medicine Stock (NASDAQ:PRME) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Prime Medicine alerts:Sign Up Key Stats Today's Range$3.73▼$4.1550-Day Range$2.88▼$5.3652-Week Range$2.67▼$5.91Volume5.57 million shsAverage Volume3.36 million shsMarket Capitalization$708.28 millionP/E RatioN/ADividend YieldN/APrice Target$7.86Consensus RatingModerate Buy Company Overview Prime Medicine is a biotechnology company developing genetic therapies for diseases caused by genetic mutations. Its research focuses on prime editing, a gene-editing technology designed to make targeted changes to DNA, including substitutions, insertions and deletions. The company is working to apply its platform to potential treatments for a range of serious conditions. Its programs are in development, and Prime Medicine does not currently market approved therapies. Founded in 2019, Prime Medicine is based in Cambridge, Massachusetts. Its technology is rooted in research by geneticist David Liu and colleagues, who helped develop prime editing.AI Generated. May Contain Errors. Read More Prime Medicine Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks74th Percentile Overall ScorePRME MarketRank™: 3.704188481675 of 5 starsPrime Medicine scored higher than 74% of companies evaluated by MarketBeat, and ranked 164th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingPrime Medicine has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 1 strong buy rating, 7 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialPrime Medicine has a consensus price target of $7.86, representing about 94.7% upside from its current price of $4.04.Amount of Analyst CoveragePrime Medicine has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Prime Medicine's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Prime Medicine are expected to grow in the coming year, from ($0.97) to ($0.87) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Prime Medicine is -3.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Prime Medicine is -3.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPrime Medicine has a P/B Ratio of 6.02. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted19.14% of the float of Prime Medicine has been sold short.Short Interest Ratio / Days to CoverPrime Medicine has a short interest ratio ("days to cover") of 4.8.Change versus previous monthShort interest in Prime Medicine has recently decreased by 11.33%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthWeak Dividend YieldPrime Medicine does not currently pay a dividend.Dividend GrowthPrime Medicine does not have a long track record of dividend growth.Read more about Prime Medicine's dividend. News and Social Media2.9 / 5News Sentiment0.69 News SentimentPrime Medicine has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 15 news articles for Prime Medicine this week, compared to 3 articles on an average week.Search InterestOnly 10 people have searched for PRME on MarketBeat in the last 30 days. This is a decrease of -9% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Prime Medicine to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership1.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Prime Medicine insiders have not sold or bought any company stock.Percentage Held by Insiders16.04% of the stock of Prime Medicine is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions70.37% of the stock of Prime Medicine is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Prime Medicine's insider trading history. Receive PRME Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Prime Medicine and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PRME Stock News HeadlinesPrime Medicine Announces Public Offering Underwriting AgreementNovember 12 at 9:31 AM | tipranks.comPrime Medicine Prices Offering Of 35.71 Mln Shares At $3.50 Per Share; Stock DownNovember 11 at 9:33 AM | rttnews.com$0. Later: $29.97.Bill Poulos is giving away his Simple Options Trading For Beginners book through a temporary link. Once that link expires, it returns to its usual price of $29.97. The content stays the same - plain-English lessons and a handful of proven techniques - only the price changes. Waiting means paying for something you could have gotten for free.November 12 at 1:00 AM | Profits Run (Ad)Prime Medicine prices $125M public offering at $3.50 per shareNovember 11 at 9:33 AM | msn.comPrime Medicine, Inc. (NASDAQ:PRME) Stock Rated "Moderate Buy" by Sell-Side BrokeragesNovember 11 at 2:48 AM | americanbankingnews.comPrime Medicine Announces Pricing of $125 Million Public Offering of Common StockNovember 10 at 9:51 PM | quiverquant.comQPrime Medicine Announces Pricing of Public Offering of Common StockNovember 10 at 9:40 PM | globenewswire.comPrime Medicine Launches Offering of Common SharesNovember 10 at 6:32 PM | marketscreener.comMSee More Headlines PRME Stock Analysis - Frequently Asked Questions How have PRME shares performed this year? Prime Medicine's stock was trading at $3.47 at the beginning of 2026. Since then, PRME shares have increased by 16.3% and is now trading at $4.0350. How were Prime Medicine's earnings last quarter? Prime Medicine, Inc. (NASDAQ:PRME) issued its earnings results on Thursday, August, 6th. The company reported ($0.24) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.24). The firm earned $1.15 million during the quarter, compared to the consensus estimate of $4.40 million. Prime Medicine had a negative net margin of 4,613.11% and a negative trailing twelve-month return on equity of 188.27%. When did Prime Medicine IPO? Prime Medicine (PRME) raised $175 million in an initial public offering on Thursday, October 20th 2022. The company issued 10,294,118 shares at a price of $16.00-$18.00 per share. Who are Prime Medicine's major shareholders? Top institutional shareholders of Prime Medicine include State Street Corp (3.39%), Sumitomo Mitsui Trust Group Inc. (1.61%), Russell Investments Group Ltd. (0.10%) and Green Alpha Advisors LLC (0.09%). Insiders that own company stock include David R Liu, Arch Venture Partners Xii, Llc and Robert Nelsen. View institutional ownership trends. How do I buy shares of Prime Medicine? Shares of PRME stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Prime Medicine own? Based on aggregate information from My MarketBeat watchlists, some other companies that Prime Medicine investors own include NVIDIA (NVDA), Palantir Technologies (PLTR), Advanced Micro Devices (AMD), Tesla (TSLA), BigBear.ai (BBAI), SoundHound AI (SOUN) and IonQ (IONQ). Company Calendar Last Earnings8/06/2026Today11/12/2026Jefferies Global Healthcare Conference11/16/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 2 weeks, PRME's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:PRME Previous SymbolNASDAQ:PRME CIK1894562 Webprimemedicine.com Phone(617) 465-0013FaxN/AEmployees146Year Founded2019Price Target and Rating Average Price Target for Prime Medicine$7.86 High Price Target$11.00 Low Price Target$6.00 Potential Upside/Downside+100.2%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($1.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$201.14 million Net Margins-4,613.11% Pretax Margin-4,613.11% Return on Equity-188.27% Return on Assets-59.11% Debt Debt-to-Equity RatioN/A Current Ratio3.05 Quick Ratio3.05 Sales & Book Value Annual Sales$4.07 million Price / Sales174.79 Cash FlowN/A Price / Cash FlowN/A Book Value$0.67 per share Price / Book5.86Miscellaneous Outstanding Shares181,377,000Free Float152,284,000Market Cap$711.90 million OptionableOptionable Beta2.14 Social Links 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (NASDAQ:PRME) was last updated on 11/12/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...American Alternative | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredDemocrats can stall every bill. They can’t stop this Trump order.The U.S. owns 8,133 tonnes of gold, still valued on the books at $42.22 an ounce. That price was set in 1973 a...Priority Gold | SponsoredMany investors are about to lose everythingTwenty five years ago, this analyst predicted the fiber optic boom and called Amazon before it became a househ...Porter & Company | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prime Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Prime Medicine With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
